miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion
Yıl: 2022 Cilt: 47 Sayı: 4 Sayfa Aralığı: 435 - 443 Metin Dili: İngilizce DOI: 10.1515/tjb-2021-0154 İndeks Tarihi: 29-05-2023
miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion
Öz: Objectives: This study aimed to examine the role of miR-221, miR-650, and miR-4534 expressions in the development, pathogenesis, and early diagnosis of pros- tate cancer. Methods: The study included 83 participants: 37 patients with PCa, 31 patients with BPH, and 15 healthy subjects. MiRNA expressions in plasma samples was evaluated by quantitative RT-PCR. Results: Plasma miR-221 and miR-4534 levels were signifi- cantly upregulated in the PCa and BPH groups compared to the control group. A significant difference was determined between the presence of lymph node metastasis and the ex- pressions of miRNAs. In the ROC analysis of the miRNAs, it was determined that the AUC for miR-221 was 0.737 with a sensitivity of 57% and specificity of 100%, AUC for miR-650 was 0.706 with a sensitivity of 62% and specificity of 93% and AUC for miR-4534 was 0.800 with a sensitivity of 73% and specificity of 93%. Conclusions: Overexpression of miR-221, miR-650, and miR-4534 may distinguish PCa and BPH from healthy controls, but seems to be insufficient in differentiating PCa from BPH when used alone or in combination. However, these oncogenic miRNAs may have a role in determining the development and progression of the disease by sup- pressing the tumor suppressor genes they target.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Cozar JM, Robles-Fernandez I, Rodriguez-Martinez A, Puche- Sanz I, Vazquez-Alonso F, Lorente JA, et al. The role of miRNAs as biomarkers in prostate cancer [Internet]. Mutat Res Rev Mutat Res 2019;781:165–74. Available from: https://pubmed.ncbi.nlm.nih. gov/31416574/. [cited 2021 May 20].
- 2. Ibrahim NH, Abdellateif MS, Kassem SHA, Abd El Salam MA, El Gammal MM. Diagnostic significance of miR-21, miR-141, miR- 18a and miR-221 as novel biomarkers in prostate cancer among Egyptian patients. Andrologia [Internet] 2019;51:e13384. Available from: https://pubmed.ncbi.nlm.nih.gov/31483058/. [cited 2021 May 8].
- 3. Pron G. Prostate-specific antigen (Psa)–based population screening for prostate cancer: an evidence-based analysis. Ont Health Technol Assess Ser [Internet] 2015;15:1–64. Available from: http://www.hqontario.ca/evidence/publications-and- ohtac- [cited 2021 May 21].
- 4. Fabris L, Ceder Y, Chinnaiyan AM, Jenster GW, Sorensen KD, Tomlins S, et al. The potential of MicroRNAs as prostate cancer biomarkers [Internet]. Eur Urol 2016;70:312–22. Available from: https://pubmed.ncbi.nlm.nih.gov/26806656/. [cited 2021 May 20].
- 5. Dall’era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, et al. Active surveillance for early-stage prostate cancer: review of the current literature [Internet]. Cancer 2008;112: 1650–9. Available from: www.interscience.wiley.com [cited 2021 May 21].
- 6. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C, Di Franco R, et al. Micrornas in prostate cancer: an overview [Internet]. Oncotarget 2017;8:50240–51. Available from: https:// pubmed.ncbi.nlm.nih.gov/28445135/. [cited 2021 May 20].
- 7. Al-Kafaji G, Said HM, Alam MA, Al Naieb ZT. Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification. Oncol Lett [Internet] 2018;16:1357–65. Available from: https://pubmed.ncbi.nlm.nih.gov/30061955/. [cited 2021 May 21].
- 8. Leidinger P, Hart M, Backes C, Rheinheimer S, Keck B, Wullich B, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. Tumor Biol [Internet]. 2016;37:10177–85. Available from: https://pubmed.ncbi. nlm.nih.gov/26831660/ [cited 2021 May 20].
- 9. Knyazev EN, Fomicheva KA, Mikhailenko DS, Nyushko KM, Samatov TR, Alekseev BY, et al. Plasma levels of hsa-miR-619-5p and hsa-miR-1184 differ in prostatic benign hyperplasia and cancer. Bull Exp Biol Med 2016;161:108–11. Available from: https://pubmed.ncbi.nlm.nih.gov/27265125/ [cited 2021 May 21].
- 10. Zuo ZH, Yu YP, Ding Y, Liu S, Martin A, Tseng G, et al. Oncogenic Activity of miR-650 in prostate cancer is mediated by suppression of CSR1 expression. Am J Pathol 2015;185:1991–9.
- 11. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 2016;7:68371–84. Available from: https:// pubmed.ncbi.nlm.nih.gov/27634912/ [cited 2021 May 8].
- 12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001;25:402–8. Available from: https://pubmed.ncbi. nlm.nih.gov/11846609/ [cited 2021 May 7].
- 13. Kiener M, Chen L, Krebs M, Grosjean J, Klima I, Kalogirou C, et al. MiR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo. BMC Cancer [Internet] 2019;19. Available from: https://pubmed.ncbi. nlm.nih.gov/31238903/ [cited 2021 May 8].
- 14. Farooqi AA, Qureshi MZ, Coskunpinar E, Naqvi SK ul H, Yaylim I, Ismail M miR-421, miR-155 and miR-650: emerging trends of regulation of cancer and apoptosis [Internet]. Asian Pac J Cancer Prev (APJCP) 2014;15:1909–12. Available from: https://pubmed. ncbi.nlm.nih.gov/24716910/ [cited 2021 May 8].
- 15. Kurul NO, Ates F, Yilmaz I, Narli G, Yesildal C, Senkul T. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease. Prostate 2019;79: 1125–32.
- 16. Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, et al. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. Prostate [Internet] 2014;74:1655–62. Available from: https://pubmed.ncbi.nlm.nih.gov/25252191/ [cited 2021 May 20].
- 17. Dülgeroğlu Y, Eroğlu O. Diagnostic performance of microRNAs in the circulation in differential diagnosis of BPH, chronic prostatitis and prostate cancer. Turkish J Biochem [Internet] 2019;44: 417–25. Available from: https://www.degruyter.com/document/ doi/10.1515/tjb-2018-0198/html [cited 2021 May 20].
- 18. Sun T, Wang Q, Balk S, Brown M, Lee GSM, Kantoff P. The role of microrna-221 and microrna-222 in androgen- independent prostate cancer cell lines. Cancer Res [Internet] 2009;69: 3356–63. Available from: www.aacrjournals.org [cited 2021 May 30].
- 19. Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol [Internet] 2011;32:583–8. Available from: https:// pubmed.ncbi.nlm.nih.gov/21274675/ [cited 2021 May 20].
- 20. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 2016;7:68371–84. Available from: https:// pubmed.ncbi.nlm.nih.gov/27634912/ [cited 2021 May 21].
- 21. Spahn M, Kneitz S, Scholz CJ, Stenger N, Rüdiger T, Ströbel P, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer [Internet] 2010;127:394–403. Available from: https://pubmed.ncbi.nlm.nih.gov/19585579/ [cited 2021 May 30].
- 22. Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumor Biol [Internet]. 2014;35:12613–7. Available from: https://link.springer.com/article/10.1007/ s13277-014-2584-7 [cited 2021 May 31].
- 23. Song CJ, Chen H, Chen LZ, Ru GM, Guo JJ, Ding QN. The potential of microRNAs as human prostate cancer biomarkers: a meta analysis of related studies. J Cell Biochem [Internet] 2018;119: 2763. Available from: pmc/articles/PMC5814937/ [cited 2022 Jan 23].
- 24. Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget 2016;7:68371–84. Available from: /pmc/ articles/PMC5356562/ [cited 2021 May 30].
- 25. Akbayır S, Muşlu N, Erden S, Bo M. Diagnostic value of microRNAs in prostate cancer patients with prostate specific antigen (PSA) levels between 2, and 10 ng/mL. Turk Urol Derg [Internet] 2016; 42:247–55. Available from: https://pubmed.ncbi.nlm.nih.gov/ 27909617/ [cited 2021 May 20].
- 26. Dülgeroğlu Y, Eroğlu O. Serum levels of miR-223-3p and miR-223- 5p in prostate diseases. MicroRNA [Internet] 2020;9:303–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33155933/ [cited 2021 May 20].
- 27. Kotb S, Mosharafa A, Essawi M, Hassan H, Meshref A, Morsy A. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer. Tumor Biol 2014;35:12613–7.
| APA | HEKIMLER OZTÜRK K, MUTLU IÇDUYGU F, ÖZGÖZ A, özorak a (2022). miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. , 435 - 443. 10.1515/tjb-2021-0154 |
| Chicago | HEKIMLER OZTÜRK KUYAS,MUTLU IÇDUYGU FADIME,ÖZGÖZ Asuman,özorak alper miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. (2022): 435 - 443. 10.1515/tjb-2021-0154 |
| MLA | HEKIMLER OZTÜRK KUYAS,MUTLU IÇDUYGU FADIME,ÖZGÖZ Asuman,özorak alper miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. , 2022, ss.435 - 443. 10.1515/tjb-2021-0154 |
| AMA | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. . 2022; 435 - 443. 10.1515/tjb-2021-0154 |
| Vancouver | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. . 2022; 435 - 443. 10.1515/tjb-2021-0154 |
| IEEE | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a "miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion." , ss.435 - 443, 2022. 10.1515/tjb-2021-0154 |
| ISNAD | HEKIMLER OZTÜRK, KUYAS vd. "miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion". (2022), 435-443. https://doi.org/10.1515/tjb-2021-0154 |
| APA | HEKIMLER OZTÜRK K, MUTLU IÇDUYGU F, ÖZGÖZ A, özorak a (2022). miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. Türk Biyokimya Dergisi, 47(4), 435 - 443. 10.1515/tjb-2021-0154 |
| Chicago | HEKIMLER OZTÜRK KUYAS,MUTLU IÇDUYGU FADIME,ÖZGÖZ Asuman,özorak alper miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. Türk Biyokimya Dergisi 47, no.4 (2022): 435 - 443. 10.1515/tjb-2021-0154 |
| MLA | HEKIMLER OZTÜRK KUYAS,MUTLU IÇDUYGU FADIME,ÖZGÖZ Asuman,özorak alper miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. Türk Biyokimya Dergisi, vol.47, no.4, 2022, ss.435 - 443. 10.1515/tjb-2021-0154 |
| AMA | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. Türk Biyokimya Dergisi. 2022; 47(4): 435 - 443. 10.1515/tjb-2021-0154 |
| Vancouver | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion. Türk Biyokimya Dergisi. 2022; 47(4): 435 - 443. 10.1515/tjb-2021-0154 |
| IEEE | HEKIMLER OZTÜRK K,MUTLU IÇDUYGU F,ÖZGÖZ A,özorak a "miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion." Türk Biyokimya Dergisi, 47, ss.435 - 443, 2022. 10.1515/tjb-2021-0154 |
| ISNAD | HEKIMLER OZTÜRK, KUYAS vd. "miR-221, miR-650 and miR-4534 as diagnostic markers in prostate cancer and their relationship with lymphatic invasion". Türk Biyokimya Dergisi 47/4 (2022), 435-443. https://doi.org/10.1515/tjb-2021-0154 |
